No profile data available.
Tandem Diabetes Care, Inc. (TNDM) is a healthcare company in the IV treatment equipment industry, based in San Diego, United States, with about 2,500 full-time employees.
It reported revenue of $1.01 billion for fiscal year 2025, up 7.9% from fiscal year 2024, and net income of -$204.71 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $254.56 million, up 5.8% from a year before. United States was its largest region in fiscal year 2025, with 70% of revenue. Its market capitalization was $1.12 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
Tandem Diabetes Care reported $1.01 billion in revenue for fiscal year 2025, up 7.9% from $940.20 million in fiscal year 2024. In Q2 2026 revenue was $254.56 million.
United States: 70% of revenue by region in fiscal year 2025, followed by International (30%).
$1.12 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (IV treatment equipment) include Insulet Corporation (PODD), ICU Medical, Inc. (ICUI), Iradimed Corporation (IRMD), Beta Bionics, Inc. (BBNX).